Vivos Therapeutics (VVOS) Receivables (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Receivables for 8 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 11.94% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was $1.4 million, a 11.94% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 272.09% from the prior year.
• Receivables was $1.4 million for Q2 2026 at Vivos Therapeutics, down from $1.8 million in the prior quarter.
• Over five years, Receivables peaked at $2.1 million in Q3 2025 and troughed at $202000.0 in Q4 2023.
• A 5-year average of $850111.1 and a median of $621500.0 in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 77.41% in 2022 and surged 370.04% in 2025, its largest moves.
• Over 5 years, Receivables stood at $457000.0 in 2022, then plunged by 55.8% to $202000.0 in 2023, then jumped by 112.87% to $430000.0 in 2024, then soared by 267.67% to $1.6 million in 2025, then declined by 9.04% to $1.4 million in 2026.
• The last three Receivables figures came in at $1.4 million (Q2 2026), $1.8 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.